Abstract 5P
Background
Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) is a rare disease in women. This subgroup shares similar biological characteristics with stage II-III breast cancer and is named occult breast cancer (OBC). This study intended to examine the clinicopathological features of OBC and compared OBC genetically with axillary lymph node metastases from breast cancer (BCAx), investigating differences in their biological behavior.
Methods
We conducted the clinical and prognostic analysis of 58 OBC patients in West China Hospital spanning from 2009 to 2021. Gemonic profiling of 12 OBC patients and 16 BCAx patients was conducted by the FoundationOne CDx (F1CDx) platform, including 324 genes along with genomic features such as TMB and MSI. Moreover, we also compared the gene mutation spectrum and relevant pathways between the two groups and both TCGA and COSMIC databases.
Results
The majority of the 58 OBC patients were HR-/HER2- subtype. OBC patients had a higher expression of breast origin-related immunohistochemical markers, such as GATA3, GCDFP15, and CK5/6. Most patients received mastectomy combined radiotherapy (50Gy/25f). OBC had a favorable overall prognosis. Radiotherapy was the independent prognostic factor in multivariate analysis (HR=0.04, 95%CI=0.00-0.85, P=0.0390). In 28 samples and 401 TCGA-BRCA patients, IRS2 only mutated in OBC (33.33%) but amplified in BCAx (11.11%) and TCGA-BRCA (1.5%). Pathway analysis revealed that BCAx had more NOTCH pathway mutations than OBC, where NOTCH3 and GATA3 was highly amplified in OBC (16.67% vs. 0%) and BCAx (16.67% vs. 0%) respectively. GATA6 only had novel mutations in BCAx (31.25%) according to the COSMIC database. Enrichment analysis showed that OBC enriched more in mammary development and PML bodies than BCAx, but less in the positive regulation of kinase activity.
Conclusions
More active treatment methods could improve the prognosis of OBC. The differential mutation genes of OBC and BCAx might be associated with their respective biological behaviors like invasiveness and prognosis. The differences in NOTCH pathway and enrichment analysis might cause the occult lesions in the OBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18022 and ZYJC21017).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract